The true narrative for Pfizer (PFE) is not its recent top line earnings beat but the escalating structural tension between ...

Pfizer is looking to newer products and acquisitions to offset a declining Covid business.

Pfizer has been leaning on recently acquired products to offset a looming patent cliff.

Pfizer (PFE) stock gained 0.5% premarket after Q1 EPS of $0.75 topped forecasts. Eliquis drove revenue strength as company ...

By Mariam Sunny and Christy Santhosh May 5 (Reuters) - Pfizer reported higher-than-expected sales and profit on Tuesday and ...

Pfizer shares were muted even as the company topped Wall Street estimates with its first quarter results and reaffirmed its ...

Revenue reached $14.45 billion, up 5% year-over-year, as oncology and other recently launched products offset steep declines ...

PFE has been testing $26 since February but has breached another key level Pfizer Inc (NYSE:PFE) stock is down 1.1% to trade ...

Pfizer (NYSE: PFE) and AbbVie (NYSE: ABBV) are two pharmaceutical giants that seem to be headed in opposite directions.

Pfizer (NYSE:PFE | PFE Price Prediction) and Moderna (NASDAQ:MRNA) just closed the books on Q4 2025, and the contrast is ...

Pfizer is buying its way back into the obesity-drug game after fighting off a rival bid from Novo Nordisk to buy Metsera, with more money and help from the Trump administration Pfizer won its fight to ...

Good day, everyone, and welcome to Pfizer's First Quarter 2026 Earnings Conference Call. Today's call is being recorded. At this time, I would like to turn the call over to Francesca DeMartino, Chief ...